Coeptis Therapeutics Inc. (NASDAQ: COEP) is a pre-clinical stage biopharmaceutical Corp focused on fighting cancer via a pipeline of potentially novel products targeting CD38+ related unmet need and solid tumor cancers. The YE22A results show wash through of the SPAC merger and redemptions, which may run around ~90%. The 1Q23A results add additional insights into operational costs in particular. During YE22A raise ‘costs’ are dominated by warrant liabilities and redemptions. The diagnostics plat ....
![working](/images/WorkingLarge.gif)
29 Jun 2023
Coeptis Therapeutics Inc. (COEP) YE22 1Q23 & DeSPAC 29062023
![](/images/orange-lock.png)
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Coeptis Therapeutics Inc. (COEP) YE22 1Q23 & DeSPAC 29062023
- Published:
29 Jun 2023 -
Author:
ACF Analyst Team -
Pages:
24 -
Coeptis Therapeutics Inc. (NASDAQ: COEP) is a pre-clinical stage biopharmaceutical Corp focused on fighting cancer via a pipeline of potentially novel products targeting CD38+ related unmet need and solid tumor cancers. The YE22A results show wash through of the SPAC merger and redemptions, which may run around ~90%. The 1Q23A results add additional insights into operational costs in particular. During YE22A raise ‘costs’ are dominated by warrant liabilities and redemptions. The diagnostics plat ....